EBR Systems Accelerates WiSE Cardiac Pacing Rollout with Surging Q4 Implants and Pivotal Study Launches

An announcement from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) is now available.

EBR Systems reported strong commercial and clinical progress in the fourth quarter of FY2025, with WiSE System case volumes doubling from the prior quarter to 18 commercial implants and total commercial and pilot implants reaching 30. The company expects to post a sharp step-up in quarterly revenue to between US$870,000 and US$935,000, driven by growing adoption under its Limited Market Release, which now includes 9 additional purchase agreements and a total of 33 trained implanting physicians, while expanding hospital readiness and reimbursement processes for the WiSE technology.
Clinically, EBR advanced two key studies that underpin its long-term growth strategy: the WiSE-UP post-approval study began enrolling patients to generate real-world performance and outcomes data across more than 300 heart failure patients over five years, and the TLC-AU feasibility study enrolled its first patient to evaluate totally leadless CRT in both upgrade and de novo candidates, potentially opening up roughly three-quarters of the CRT market to WiSE as a first-line option. The company also intensified its investor outreach through multiple healthcare and small/mid-cap conferences and roadshows, reinforcing its profile with the investment community as it builds the evidence base and commercial infrastructure needed for broader market adoption of its wireless pacing platform.

The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.

More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

EBR Systems, Inc. is a medical technology company focused on treating heart failure through its WiSE System, the world’s only wireless cardiac pacing device designed to deliver left ventricular endocardial pacing for cardiac resynchronization therapy. The company targets patients for whom conventional lead-based CRT is ineffective or impractical and is working to expand its addressable market into de novo CRT patients and totally leadless pacing solutions.

Average Trading Volume: 572,936

Technical Sentiment Signal: Sell

Current Market Cap: A$443.2M

Find detailed analytics on EBR stock on TipRanks’ Stock Analysis page.